155 related articles for article (PubMed ID: 16219908)
1. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
Dasmahapatra G; Almenara JA; Grant S
Mol Pharmacol; 2006 Jan; 69(1):288-98. PubMed ID: 16219908
[TBL] [Abstract][Full Text] [Related]
2. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
3. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Gao N; Dai Y; Rahmani M; Dent P; Grant S
Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
Rosato RR; Almenara JA; Dai Y; Grant S
Mol Cancer Ther; 2003 Dec; 2(12):1273-84. PubMed ID: 14707268
[TBL] [Abstract][Full Text] [Related]
5. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Almenara J; Rosato R; Grant S
Leukemia; 2002 Jul; 16(7):1331-43. PubMed ID: 12094258
[TBL] [Abstract][Full Text] [Related]
6. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
[TBL] [Abstract][Full Text] [Related]
7. Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis.
Decker RH; Wang S; Dai Y; Dent P; Grant S
Cancer Biol Ther; 2002; 1(2):136-44. PubMed ID: 12170773
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).
Tang L; Boise LH; Dent P; Grant S
Biochem Pharmacol; 2000 Nov; 60(10):1445-56. PubMed ID: 11020446
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Maggio SC; Rosato RR; Kramer LB; Dai Y; Rahmani M; Paik DS; Czarnik AC; Payne SG; Spiegel S; Grant S
Cancer Res; 2004 Apr; 64(7):2590-600. PubMed ID: 15059916
[TBL] [Abstract][Full Text] [Related]
10. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
Pei XY; Dai Y; Grant S
Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
[TBL] [Abstract][Full Text] [Related]
11. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Dai Y; Rahmani M; Grant S
Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
[TBL] [Abstract][Full Text] [Related]
13. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.
Rosato RR; Almenara JA; Cartee L; Betts V; Chellappan SP; Grant S
Mol Cancer Ther; 2002 Feb; 1(4):253-66. PubMed ID: 12467221
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol.
Cartee L; Maggio SC; Smith R; Sankala HM; Dent P; Grant S
Mol Cancer Ther; 2003 Jan; 2(1):83-93. PubMed ID: 12533676
[TBL] [Abstract][Full Text] [Related]
15. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
16. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Rosato RR; Almenara JA; Kolla SS; Maggio SC; Coe S; Giménez MS; Dent P; Grant S
Mol Cancer Ther; 2007 Feb; 6(2):692-702. PubMed ID: 17308065
[TBL] [Abstract][Full Text] [Related]
17. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
[TBL] [Abstract][Full Text] [Related]
18. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.
Rosato RR; Almenara JA; Yu C; Grant S
Mol Pharmacol; 2004 Mar; 65(3):571-81. PubMed ID: 14978235
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Rosato RR; Almenara JA; Maggio SC; Atadja P; Craig R; Vrana J; Dent P; Grant S
Mol Cancer Ther; 2005 Nov; 4(11):1772-85. PubMed ID: 16275999
[TBL] [Abstract][Full Text] [Related]
20. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
Mitchell C; Park MA; Zhang G; Yacoub A; Curiel DT; Fisher PB; Roberts JD; Grant S; Dent P
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3101-12. PubMed ID: 18065490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]